

## Editorial

## Is There Room for Theophylline in COPD?☆

## ¿Hay un lugar para la teofilina en la EPOC?

Núria Toledo-Pons, Borja G. Cosío\*

Servicio de Neumología, Hospital Universitario Son Espases-IdISBa Ciber de Enfermedades Respiratorias (Ciberes), Palma de Mallorca, Spain



Theophylline, which is inexpensive and widely available, remains one of the most commonly prescribed drugs worldwide for the treatment of asthma and COPD. Data from some studies show that it is still being prescribed in 35% of patients with COPD.<sup>1</sup> Despite it being used the world over, in industrialized countries the role of theophylline has changed dramatically in the last decades, and it has become a third-line treatment for poorly-controlled patients.<sup>2,3</sup> This change was due mainly to the introduction of new drugs with more favorable efficacy and safety profiles, such as  $\beta_2$ -agonists and inhaled corticosteroids (ICS).

Oral theophylline has been used in COPD for its bronchodilatory properties for more than 70 years. Its mechanism of action is based on the non-selective inhibition of phosphodiesterase and the increase of intracellular cAMP, which relaxes the smooth muscle of the airways. However, this non-selective inhibition of phosphodiesterase causes a wide range of side effects (nausea, vomiting, abdominal pain, metabolic acidosis, seizures, and arrhythmias), which largely restricts the therapeutic range of theophylline (10–20 mg/l); however, to achieve modest clinical effects, relatively high plasma levels over 10 mg/l are needed. We also now know that the bronchodilatory effect of theophylline is weak and, according to an *in vitro* study,<sup>4</sup> the plasma concentration necessary to ensure an optimum effect is 67 mg/l, much higher than that used in clinical practice. For all these reasons, it is not surprising that high-dose theophylline has gradually been replaced by inhaled bronchodilators.

In 2002, Ito et al. described for the first time a new mechanism of action of theophylline. These authors reported a preclinical study in COPD patients, in which oral low-dose theophylline (1–5 mg/l) increased the sensitivity of airway inflammation to the anti-inflammatory effects of ICS. This new anti-inflammatory effect is a result of increased histone deacetylase (HDAC) activity that enhances the anti-inflammatory effect of glucocorticoids by decreasing the expression of proinflammatory genes.<sup>5</sup> Following publication of this study, other groups have confirmed these findings and added to the understanding of the *in vitro* and *ex vivo*

mechanisms.<sup>6,7</sup> Some groups have even indirectly correlated some of the molecular changes induced by the combination of theophylline and ICS (increase in hydrogen sulfide [H<sub>2</sub>S] concentration) with improved lung function.<sup>8</sup> These data provided a scientific basis to support the pharmacological use of theophylline combined with ICS.

However, few studies are available on the clinical effects of low-dose theophylline *in vivo*, and results are variable. The administration of oral low-dose theophylline in patients with COPD exacerbations significantly reduced HDAC activity in sputum macrophages at 3 months, and could be due to the concomitant administration of oral corticosteroids.<sup>9</sup> In a study in India, COPD patients treated with ICS and low-dose theophylline presented a lower degree of dyspnea and better results in the 6-minute walk test and lung function (pre-bronchodilator FEV<sub>1</sub>).<sup>10</sup> In contrast, in a clinical trial recently published by our group,<sup>11</sup> COPD patients treated with ICS and low-dose theophylline showed no differences in exacerbation rates compared to the group that received ICS alone. This study was unable to confirm *in vivo* any increase in HDAC activity, the molecular antiinflammatory effect previously observed *in vitro*.<sup>5</sup>

In any case, because of its modest bronchodilatory effect, limited and controversial evidence of the oral antiinflammatory effect, and narrow therapeutic range, theophylline is a third-line treatment in current clinical practice guidelines,<sup>12,13</sup> and its use is reserved as a therapeutic option in severely ill patients who do not respond to conventional drugs.

Does this point to the end of theophylline? The availability of the drug and the numerous *in vitro* and *ex vivo* studies that show improvements in the anti-inflammatory efficacy of corticosteroids when combined with low-dose theophylline oblige us, at least, to look for new routes of administration, which might perhaps include the combined administration of the two drugs by inhalation, to confirm if the *in vitro* effects are also reflected in clinically relevant outcomes. Until then, theophylline in COPD will probably continue to be the last option in severely ill patients who fail to respond to previous treatment lines.

## References

1. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al., UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med*. 2008;359:1543–54.

☆ Please cite this article as: Toledo-Pons N, Cosío BG. ¿Hay un lugar para la teofilina en la EPOC? *Arch Bronconeumol*. 2017;53:539–540.

\* Corresponding author.

E-mail address: [borja.cosio@ssib.es](mailto:borja.cosio@ssib.es) (B.G. Cosío).

2. Barnes PJ. Theophylline. *Am J Respir Crit Care Med.* 2013;188:901–6.
3. Rabe KF, Hurd S, Anzueto A, Anzueto A, Barnes PJ, Buist SA, et al. Global strategy for the diagnosis management, and prevention of chronic obstructive pulmonary disease GOLD executive summary. *Am J Respir Crit Care Med.* 2007;176:532–55.
4. Barnes PJ. Theophylline: new perspectives for an old drug. *Am J Respir Crit Care Med.* 2003;167:813–8.
5. Ito K, Lim S, Caramori G, Cosío B, Chung KF, Adcock IM, et al. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. *Proc Natl Acad Sci U S A.* 2002;99:8921–6.
6. Gallelli L, Falcone D, Cannataro R, Perri M, Serra R, Pelaia G, et al. Theophylline action on primary human bronchial epithelial cells under proinflammatory stimuli and steroidal drugs: a therapeutic rationale approach. *Drug Des Dev Ther.* 2017;11:265–72.
7. Ford PA, Durhan AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. *Chest.* 2010;137:1338–44.
8. Kirkham PA, Whiteman M, Winyard PG, Caramori G, Gordon F, Ford PA, et al. Impact of theophylline/corticosteroid combination therapy on sputum hydrogen sulfide levels in patients with COPD. *Eur Respir J.* 2014;43:1504–6.
9. Cosío BG, Iglesias A, Rios A, Noguera A, Sala E, Ito K, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. *Thorax.* 2009;64:424–9.
10. Subramanian R, Jindal A, Viswambhar V, Babu A. The study of efficacy, tolerability and safety of theophylline given along with formoterol plus budesonide in COPD. *J Clin Diagn Res.* 2015;9:OC10–3.
11. Cosío BG, Shafiek H, Iglesias A, Yanez A, Córdova R, Palou A, et al. Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial. *Chest.* 2016;150:123–30.
12. Global Strategy for the Diagnosis, Management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2017. Available from: <http://goldcopd.org> [accessed 05.06.17].
13. Miravittles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al., Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological treatment of stable phase. *Arch Bronconeumol.* 2017;53:324–35.